 SAN DIEGO, Nov. 04, 2022 GLOBE NEWSWIRE -- Fate Therapeutics, Inc. the Company or Fate Therapeutics NASDAQ: FATE, a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for patients with cancer, today announced that the Company will present at the following upcoming investor conferences: 